SEQUELA AND RISKS OF COVID-19 VACCINES
Keywords:
COVID -19, risks, sequela, nursing, vaccinesAbstract
Billions of people around the world are vaccinated with the COVI19 vaccine. The virus that claimed the lives of millions of people of different races and ages, and the antiviral vaccine is an important means of preventing and protecting against infection for a period of time. Data of the present study which conducted in Basrah city southern of Iraq , showed that male 46% of the vaccinated participants were male more than female ,59% of them between 23 -30 years of age,72% vaccinated with Pfizer and most of them showed symptom for post vaccination after 1-6 day. Fever significantly rise with Pfizer vaccine, post vaccinated complication correlated with persons have chronic diseases , post complications symptom correlate with age and period, ,sex and work are not significant .
References
Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. 7749790. PMID 33341119.
Richie H, Ortiz-Ospina E, Beltekian D, Methieu E, Hasell J, Macdonald B, et al. (5 March 2020). "Coronavirus (COVID-19) Vaccinations – Statistics and Research". Our World in Data. Retrieved 7 February 2021.
Mullard A (November 2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID 227246811.
"Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization (WHO). 27 April 2020.
641.2004.01272.x. PMID 15479434. S2CID 154670.
"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu)". ClinicalTrials.gov. 12 May 2020. NCT04383574. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)". ClinicalTrials.gov. 2 July 2020. NCT04456595. Archived from the original on 11 October 2020. Retrieved 3 August 2020.
PT. Bio Farma (10 August 2020). "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia". Registri Penyakit Indonesia. Archived from the original on 11 October 2020. Retrieved 15 August 2020.
Chen W, Al Kaabi N (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Retrieved 15 August 2020.
Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Retrieved 11 April 2021.
"Kazakhstan rolls out its own COVID-19 vaccine". Reuters. 27 April 2021. Retrieved 2 July 2021.
"FarsNews Agency Iran Licenses Emergency Injection of Home-Made Anti-Coronavirus Vaccine". Fars News Agency. 14 June 2021. Retrieved 25 August 2021.
"VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.
oronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 4 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. (6 October 2021). "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months". New England Journal of Medicine. 385 (24): e84.
doi:10.1056/NEJMoa2114583. PMC 8522797. PMID 34614326.
Hind B Almufty 1, Shinah A Mohammed 2, Arshad M Abdullah 3, Muayad A MerzaPotential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional studyDiabetes Metab Syndr, . Sep-Oct 2021;15(5):102207. doi:
1016/j.dsx.2021.102207. Epub 2021 Jul 12.
Andrzejczak-Grządko S, Czudy Z, DonderskaM :Side effects after COVID-19 vaccinations among residents of PolandEur Rev Med Pharmacol Sci. 2021 Jun;25(12):4418-4421. doi: 10.26355/eurrev_202106_26153.
Anne M Hause, James Baggs, Julianne Gee, Paige Marquez, Tanya R Myers, Tom T Shimabukuro, David K Shay : Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021:MMWR Morb Mortal Wkly Rep, .2021 Oct 1;70(39):1379-1384. doi: 10.15585/mmwr.mm7039e4.
Meo S A, Bukhari A, Akram J, Meo A S, Klonoff ,D C. :COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines:Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
CDC. COVID-19 vaccination: clinical considerations. Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/anaphylaxismanagement.html
WASFI DHAHIR ABID ALI , LUAY ABDULWAHID SHIHAB , MARYAM ABDULKAREEM
ABDULRAZAQ , NOOR SABAH DAIF , & NABAAMUSSAB HASSAN, ASSESSMENT OF TEACHERS’ KNOWLEDGE ABOUT FIRST AID SOME BASRAH CITY SCHOOLS, BEST: International Journal of Humanities, Arts, Medicine and Sciences (BEST: IJHAMS) ISSN (P): 2348–0521, ISSN (E): 2454–4728 Vol. 9, Issue 02, Feb 2021, 7–12.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
